ECTRIMS 2022 | Blood serum proteome correlates of MS disease progression: a 5-year longitudinal study

Nowadays, there are no tools available to measure disease progression quantitatively in clinical practice, but its availability would enhance the care of multiple sclerosis (MS) patients. Ferhan Qureshi, BS, Vice President, Octave Bioscience, Menlo Park, CA, discusses a study that aimed to quantify proteomic correlates of disease progression. Blood serum samples from MS patients were collected at two time-points, one at baseline and one at 5 years, and clinical and radiographic data associated with the samples were available. The study investigated the performance of the MSDA test algorithm previously validated for disease activity assessments in a different cohort. The MSDA test algorithm replicated performance for accurately categorizing patient disease activity levels (low, moderate, and high). Next, the scores and the concentrations of individual biomarkers were analyzed relative to the clinical and radiographic disease progression endpoints, including Expanded Disability Status Score (EDSS) and MRI brain volumetry. Results showed that measurable effects of disease progression via individual biomarkers were detected in the serum proteome. These results highlight the opportunity to build upon the univariate findings and build multivariate models specific for progression. This interview took place at the ECTRIMS Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.